LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 75

Search options

  1. Article ; Online: Updates in Molecular Breast Imaging.

    Hruska, Carrie B

    Seminars in roentgenology

    2021  Volume 57, Issue 2, Page(s) 134–138

    Abstract: Molecular breast imaging (MBI) is a nuclear medicine study performed with dedicated gamma camera systems optimized to image the uptake of Tc-99m sestamibi in the breast. MBI provides a relatively low-cost and simple functional breast imaging method that ... ...

    Abstract Molecular breast imaging (MBI) is a nuclear medicine study performed with dedicated gamma camera systems optimized to image the uptake of Tc-99m sestamibi in the breast. MBI provides a relatively low-cost and simple functional breast imaging method that can identify breast cancers obscured by dense fibroglandular tissue on mammography. Recent studies have also found that background levels of uptake in benign dense tissue may provide breast cancer risk information. This article discusses the latest updates in MBI technology, recent evidence supporting its clinical use, and work in progress that may aid in wider adoption of MBI.
    MeSH term(s) Breast/diagnostic imaging ; Breast Neoplasms/diagnostic imaging ; Female ; Gamma Cameras ; Humans ; Mammography/methods ; Molecular Imaging/methods ; Radiopharmaceuticals ; Technetium Tc 99m Sestamibi
    Chemical Substances Radiopharmaceuticals ; Technetium Tc 99m Sestamibi (971Z4W1S09)
    Language English
    Publishing date 2021-12-31
    Publishing country United States
    Document type Journal Article
    ZDB-ID 80310-8
    ISSN 1558-4658 ; 0037-198X
    ISSN (online) 1558-4658
    ISSN 0037-198X
    DOI 10.1053/j.ro.2021.12.006
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Let's Get Real about Molecular Breast Imaging and Radiation Risk.

    Hruska, Carrie B

    Radiology. Imaging cancer

    2019  Volume 1, Issue 1, Page(s) e190070

    MeSH term(s) Breast/diagnostic imaging ; Mammography/adverse effects ; Odds Ratio ; Risk
    Language English
    Publishing date 2019-09-27
    Publishing country United States
    Document type Journal Article ; Comment
    ISSN 2638-616X
    ISSN (online) 2638-616X
    DOI 10.1148/rycan.2019190070
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Comment on "Radiation Doses and Risks in Breast Screening".

    Conners, Amy Lynn / Ellis, Richard / Fazzio, Robert T / Hruska, Carrie B / Hunt, Katie N / O'Connor, Michael K / Rhodes, Deborah J / Shermis, Robin

    Journal of breast imaging

    2024  Volume 2, Issue 6, Page(s) 519–520

    Language English
    Publishing date 2024-02-29
    Publishing country United States
    Document type Journal Article
    ISSN 2631-6129
    ISSN (online) 2631-6129
    DOI 10.1093/jbi/wbaa074
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Molecular Breast Imaging for Screening in Dense Breasts: State of the Art and Future Directions.

    Hruska, Carrie B

    AJR. American journal of roentgenology

    2017  Volume 208, Issue 2, Page(s) 275–283

    Abstract: Objective: The purposes of this review are to discuss the motivation for supplemental screening, to address molecular breast imaging (MBI) radiation dose concerns, and to provide an updated guide to current MBI technology, clinical protocols, and ... ...

    Abstract Objective: The purposes of this review are to discuss the motivation for supplemental screening, to address molecular breast imaging (MBI) radiation dose concerns, and to provide an updated guide to current MBI technology, clinical protocols, and screening performance. Future directions of MBI are also discussed.
    Conclusion: MBI offers detection of mammographically occult cancers in women with dense breasts. Although MBI has been under investigation for nearly 15 years, it has yet to gain widespread adoption in breast screening.
    MeSH term(s) Absorptiometry, Photon ; Biomarkers, Tumor/metabolism ; Breast Density ; Breast Neoplasms/diagnostic imaging ; Breast Neoplasms/metabolism ; Early Detection of Cancer/trends ; Female ; Forecasting ; Humans ; Mammography/trends ; Molecular Imaging/trends ; Reproducibility of Results ; Sensitivity and Specificity
    Chemical Substances Biomarkers, Tumor
    Language English
    Publishing date 2017-02
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 82076-3
    ISSN 1546-3141 ; 0361-803X ; 0092-5381
    ISSN (online) 1546-3141
    ISSN 0361-803X ; 0092-5381
    DOI 10.2214/AJR.16.17131
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: PPV of the Molecular Breast Imaging Lexicon.

    Hunt, Katie N / Conners, Amy Lynn / Samreen, Naziya / Rhodes, Deborah / Johnson, Matthew P / Hruska, Carrie B

    AJR. American journal of roentgenology

    2022  

    Abstract: Background: ...

    Abstract Background:
    Language English
    Publishing date 2022-07-20
    Publishing country United States
    Document type Journal Article
    ZDB-ID 82076-3
    ISSN 1546-3141 ; 0361-803X ; 0092-5381
    ISSN (online) 1546-3141
    ISSN 0361-803X ; 0092-5381
    DOI 10.2214/AJR.21.27047
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Breast Cancer Mode of Detection in a Population-Based Cohort.

    Basappa, Susanna N / Finney Rutten, Lila J / Hruska, Carrie B / Olson, Janet E / Jacobson, Debra J / Rhodes, Deborah J

    Mayo Clinic proceedings

    2023  Volume 98, Issue 2, Page(s) 278–289

    Abstract: Objective: To evaluate how breast cancers come to clinical attention (mode of detection [MOD]) in a population-based cohort, determine the relative frequency of different MODs, and characterize patient and tumor characteristics associated with MOD.: ... ...

    Abstract Objective: To evaluate how breast cancers come to clinical attention (mode of detection [MOD]) in a population-based cohort, determine the relative frequency of different MODs, and characterize patient and tumor characteristics associated with MOD.
    Patients and methods: We used the Rochester Epidemiology Project to identify women ages 40 to 75 years with a first-time diagnosis of breast cancer from May 9, 2017, to May 9, 2019 (n=500) in a 9-county region in Minnesota. We conducted a retrospective medical record review to ascertain the relative frequency of MODs, evaluating differences between screening mammography vs all other MODs by breast density and cancer characteristics. Multiple logistic regression was conducted to examine the likelihood of MOD for breast density and stage of disease.
    Results: In our population-based cohort, 162 of 500 breast cancers (32.4%) were detected by MODs other than screening mammography, including 124 (24.8%) self-detected cancers. Compared with women with mammography-detected cancers, those with MODs other than screening mammography were more frequently younger than 50 years of age (P=.004) and had higher-grade tumors (P=.007), higher number of positive lymph nodes (P<.001), and larger tumor size (P<.001). Relative to women with mammography-detected cancers, those with MODs other than screening mammography were more likely to have dense breasts (odds ratio, 1.87; 95% CI, 1.20 to 2.92; P=.006) and advanced cancer at diagnosis (odds ratio, 3.58; 95% CI, 2.29 to 5.58; P<.001).
    Conclusion: One-third of all breast cancers in this population were detected by MODs other than screening mammography. Increased likelihood of nonmammographic MODs was observed among women with dense breasts and advanced cancer.
    MeSH term(s) Female ; Humans ; Adult ; Middle Aged ; Aged ; Breast Neoplasms/diagnosis ; Breast Neoplasms/epidemiology ; Breast Neoplasms/pathology ; Mammography ; Retrospective Studies ; Mass Screening ; Early Detection of Cancer
    Language English
    Publishing date 2023-02-03
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 124027-4
    ISSN 1942-5546 ; 0025-6196
    ISSN (online) 1942-5546
    ISSN 0025-6196
    DOI 10.1016/j.mayocp.2022.10.010
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Molecular Breast Imaging in Patients with Suspicious Calcifications.

    Hunt, Katie N / Hruska, Carrie B / Johnson, Matthew P / Conners, Amy Lynn / O'connor, Michael K / Rhodes, Deborah J / Basappa, Susanna / Wahner-Roedler, Dietlind

    Journal of breast imaging

    2024  Volume 1, Issue 4, Page(s) 303–309

    Abstract: Objective: We evaluated the accuracy of molecular breast imaging (MBI)-a nuclear medicine technique that employs dedicated dual-detector, cadmium zinc telluride gamma cameras to image the functional uptake of a radiopharmaceutical (typically Tc-99m ... ...

    Abstract Objective: We evaluated the accuracy of molecular breast imaging (MBI)-a nuclear medicine technique that employs dedicated dual-detector, cadmium zinc telluride gamma cameras to image the functional uptake of a radiopharmaceutical (typically Tc-99m sestamibi) in the breast-in patients with suspicious calcifications on mammography.
    Methods: Women scheduled for stereotactic biopsy of calcifications detected on 2D digital mammography were prospectively enrolled to undergo MBI before biopsy. Molecular breast imaging was performed with injection of Tc-99m sestamibi and a dual-detector, cadmium zinc telluride gamma camera. Positive findings on either modality were biopsied. High-risk and malignant biopsy findings were excised.
    Results: In 71 participants, 76 areas of calcifications were recommended for biopsy after mammography, and 24 (32%) were malignant, including 20 cases of ductal carcinoma in situ (DCIS) and 4 cases of invasive ductal cancer. Prebiopsy MBI was positive in 17 of the 76 (22%) calcifications, including 10 of 20 (50%) DCISs and 2 of 4 (50%) invasive cancers. The median pathologic size for MBI-positive cancers was 1.5 cm (range 0.5-3.2 cm) compared with 0.9 cm (range 0.1-2.0 cm) for MBI-negative cancers (P = 0.09).Non-mass uptake on MBI led to additional biopsies of 6 sites in 6 patients, and 2 of 6 (33%) MBI-detected incidental lesions showed malignancy; both DCIS contralateral to the mammographically detected calcifications. The overall per-lesion positive and negative predictive values of MBI in this prebiopsy setting were 61% (14 of 23) and 80% (47 of 59), respectively.
    Conclusion: Molecular breast imaging has insufficient negative predictive value to identify calcifications in which biopsy could be avoided. However, among women presenting for biopsy of suspicious calcifications, MBI revealed additional sites of mammographically occult breast cancer.To avoid biopsy of suspicious calcifications on mammography, negative findings on MBI should not be used.
    Language English
    Publishing date 2024-02-29
    Publishing country United States
    Document type Journal Article
    ISSN 2631-6129
    ISSN (online) 2631-6129
    DOI 10.1093/jbi/wbz054
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: A Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements.

    Burkett, Brian J / Bartlett, David J / McGarrah, Patrick W / Lewis, Akeem R / Johnson, Derek R / Berberoğlu, Kezban / Pandey, Mukesh K / Packard, Annie T / Halfdanarson, Thorvardur R / Hruska, Carrie B / Johnson, Geoffrey B / Kendi, A Tuba

    Radiology. Imaging cancer

    2023  Volume 5, Issue 4, Page(s) e220157

    Abstract: Theranostics is the combination of two approaches-diagnostics and therapeutics-applied for decades in cancer imaging using radiopharmaceuticals or paired radiopharmaceuticals to image and selectively treat various cancers. The clinical use of ... ...

    Abstract Theranostics is the combination of two approaches-diagnostics and therapeutics-applied for decades in cancer imaging using radiopharmaceuticals or paired radiopharmaceuticals to image and selectively treat various cancers. The clinical use of theranostics has increased in recent years, with U.S. Food and Drug Administration (FDA) approval of lutetium 177 (
    MeSH term(s) United States ; Male ; Humans ; Precision Medicine ; Radiopharmaceuticals/therapeutic use ; Positron Emission Tomography Computed Tomography ; Radioisotopes/therapeutic use ; Neoplasms/diagnostic imaging ; Neoplasms/therapy
    Chemical Substances Radiopharmaceuticals ; Radioisotopes
    Language English
    Publishing date 2023-07-16
    Publishing country United States
    Document type Journal Article ; Review
    ISSN 2638-616X
    ISSN (online) 2638-616X
    DOI 10.1148/rycan.220157
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Molecular breast imaging detected invasive lobular carcinoma in dense breasts: A case report.

    Samreen, Naziya / Hunt, Katie N / Hruska, Carrie B / Rhodes, Deborah J

    Clinical case reports

    2019  Volume 7, Issue 3, Page(s) 442–444

    Abstract: This case highlights the role of molecular breast imaging (MBI) in evaluating persistent clinical concerns after a negative diagnostic mammogram and ultrasound. MBI is especially useful in the diagnosis of invasive lobular carcinoma due to its occult ... ...

    Abstract This case highlights the role of molecular breast imaging (MBI) in evaluating persistent clinical concerns after a negative diagnostic mammogram and ultrasound. MBI is especially useful in the diagnosis of invasive lobular carcinoma due to its occult nature on conventional imaging modalities.
    Language English
    Publishing date 2019-01-28
    Publishing country England
    Document type Case Reports
    ZDB-ID 2740234-4
    ISSN 2050-0904
    ISSN 2050-0904
    DOI 10.1002/ccr3.1945
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: 123I Scan With Whole-Body Retention Measurement at 48 Hours for Simplified Dosimetry Before 131I Treatment of Metastatic Thyroid Cancer.

    Durski, Jolanta M / Hruska, Carrie B / Bogsrud, Trond V / Ryder, Mabel / Johnson, Geoffrey B

    Clinical nuclear medicine

    2020  Volume 46, Issue 3, Page(s) e151–e153

    Abstract: Abstract: A previously published model (Atkins) allows for calculation of 131I maximum tolerated activity on the basis of 48-hour whole-body retention of 131I on a pretherapy diagnostic scan. Our practice uses iodine 123I for diagnostic imaging of ... ...

    Abstract Abstract: A previously published model (Atkins) allows for calculation of 131I maximum tolerated activity on the basis of 48-hour whole-body retention of 131I on a pretherapy diagnostic scan. Our practice uses iodine 123I for diagnostic imaging of metastatic thyroid cancer for staging before 131I therapy, with images typically acquired 24 hours after administration of the radiopharmaceutical. We explored the feasibility of an additional 123I whole-body scan and retention measurement at 48 hours, with application of the model to estimate maximum tolerated activity of radioiodine before 131I treatment of metastatic thyroid cancer.
    MeSH term(s) Adult ; Female ; Humans ; Iodine Radioisotopes/therapeutic use ; Male ; Middle Aged ; Neoplasm Metastasis ; Radiometry ; Thyroid Neoplasms/diagnostic imaging ; Thyroid Neoplasms/pathology ; Thyroid Neoplasms/radiotherapy ; Time Factors ; Whole Body Imaging
    Chemical Substances Iodine Radioisotopes ; Iodine-131 ; Iodine-123 (8YWR746RPQ)
    Language English
    Publishing date 2020-12-15
    Publishing country United States
    Document type Journal Article
    ZDB-ID 197628-x
    ISSN 1536-0229 ; 0363-9762
    ISSN (online) 1536-0229
    ISSN 0363-9762
    DOI 10.1097/RLU.0000000000003464
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top